Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER) is a research paper published in Clinical Gastroenterology and Hepatology (2023). On theSindex it has a DataRank of 2.4. It has been cited 91 times, with 79 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.678
From this paper's citation signal
Citation Network Contribution
1.7
From 57 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 79 citers.
National Institutes of Health
Grant: GPP 2022
National Institutes of Health
Grant: K23 KD111995-01A1
Takeda Pharmaceutical Company
Takeda Pharmaceuticals USA Inc
FWCI
19.90
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals